

**Figure 1: Survival curves for various antibody treatments in a murine model of B-cell lymphoma.**

The graph displays the percentage survival of mice over 80 days for five different treatment groups. The y-axis represents % Survival (0 to 125), and the x-axis represents Days (0 to 80). The legend identifies the following groups:

- Rituxan**: Solid line with open circles.
- 255.7 BCMA MAb**: Solid line with open circles.
- 238.18 neg. control MAb**: Solid line with filled circles.
- 248.24 TACI MAb**: Dashed line with open triangles.
- 255.7+248.24 BCMA+TACI MAb**: Dashed line with open squares.

The 238.18 neg. control MAb group shows the earliest and steepest decline in survival, reaching 0% by day 40. The 255.7+248.24 BCMA+TACI MAb group shows the highest survival, remaining above 80% throughout the 80-day period. The 248.24 TACI MAb group shows intermediate survival, reaching approximately 15% by day 65. The Rituxan and 255.7 BCMA MAb groups show similar survival curves, reaching approximately 15% by day 65.

Days	Rituxan (%)	255.7 BCMA MAb (%)	238.18 neg. control MAb (%)	248.24 TACI MAb (%)	255.7+248.24 BCMA+TACI MAb (%)
0	100	100	100	100	100
20	100	100	100	100	100
25	65	65	65	100	100
30	65	65	50	100	100
35	65	65	30	100	100
40	65	65	0	85	100
45	65	65	0	55	100
50	65	65	0	30	100
55	35	35	0	15	100
60	35	35	0	15	85
65	35	35	0	15	85
70	35	35	0	15	85

Figure 1